Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.5980 USD
52.98 M USD
18.22 M USD
100.33 M
About Evofem Biosciences, Inc.
Sector
Industry
CEO
Saundra L. Pelletier
Website
Headquarters
San Diego
Founded
2007
FIGI
BBG007BW54K5
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate), a hormone-free vaginal gel and EVO100, an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of EVFM is 0.0098 USD — it has decreased by −1.90% in the past 24 hours. Watch Evofem Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Evofem Biosciences, Inc. stocks are traded under the ticker EVFM.
EVFM stock has fallen by −24.62% compared to the previous week, the month change is a −6.22% fall, over the last year Evofem Biosciences, Inc. has showed a −86.00% decrease.
EVFM reached its all-time high on Aug 4, 2015 with the price of 169,277.5127 USD, and its all-time low was 0.0060 USD and was reached on Jul 1, 2024. View more price dynamics on EVFM chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
EVFM stock is 12.24% volatile and has beta coefficient of −0.64. Track Evofem Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Evofem Biosciences, Inc. there?
Today Evofem Biosciences, Inc. has the market capitalization of 983.22 K, it has increased by 1.94% over the last week.
Yes, you can track Evofem Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Evofem Biosciences, Inc. is going to release the next earnings report on Mar 26, 2025. Keep track of upcoming events with our Earnings Calendar.
EVFM net income for the last quarter is −2.37 M USD, while the quarter before that showed 1.35 M USD of net income which accounts for −275.06% change. Track more Evofem Biosciences, Inc. financial stats to get the full picture.
No, EVFM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 25, 2024, the company has 37.00 employees. See our rating of the largest employees — is Evofem Biosciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Evofem Biosciences, Inc. EBITDA is −9.58 M USD, and current EBITDA margin is −88.19%. See more stats in Evofem Biosciences, Inc. financial statements.
Like other stocks, EVFM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Evofem Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Evofem Biosciences, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Evofem Biosciences, Inc. stock shows the sell signal. See more of Evofem Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.